Thelansis

Sialorrhea Market Outlook Thelansis’s “Sialorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sialorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do interviewed ex...

  Sialorrhea Market Outlook Thelansis’s “Sialorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sialorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Sialorrhea Overview Sialorrhea, also termed ptyalis or drooling, is an incapacitating phenomenon characterized by an excess accumulation of saliva in the oral cavity extending beyond the labial boundary. While drooling is common in typically developing infants, its prevalence diminishes between 15 to 36 months of age with the establishment of salivary control. Post the age of 4; this condition is regarded as abnormal. Pathological sialorrhea may arise as an isolated event...

  Sialorrhea, also termed ptyalis or drooling, is an incapacitating phenomenon characterized by an excess accumulation of saliva in the oral cavity extending beyond the labial boundary. While drooling is common in typically developing infants, its prevalence diminishes between 15 to 36 months of age with the establishment of salivary control. Post the age of 4; this condition is regarded as abnormal. Pathological sialorrhea may arise as an isolated event due to heightened salivary secretion or may manifest concomitantly with various neurological conditions like amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), cerebral palsy (CP), or as an adverse effect of medications. In the pediatric population, CP is the leading cause of sialorrhea, persisting in 10%–38% of affected individuals. Conversely, PD is the predominant etiological factor in adults, accounting for sialorrhea in 70%–80% of PD patients. Notably, using clozapine in schizophrenic patients results in hypersal...